Episode 178 - April 3, 2026

What It Covers

Biotech Hangout Episode 178 covers Q1 2026 biotech market performance, three major M&A deals (Biogen/Apellis at $5.6B, Eli Lilly/Centessa at $6B, Cyclerion/Corsana reverse merger), FDA regulatory shifts favoring orphan drugs, Lilly's oral GLP-1 approval, blood-brain barrier shuttle technology momentum, and competitive dynamics in obesity, narcolepsy, and sickle cell disease markets.

Key Questions Answered

• •Biotech Sector Outperformance: XBI is up 7.4% year-to-date while the S&P 500 is down approximately 4%, representing over 11% relative outperformance. Investors should treat macro-driven pullbacks as buying opportunities rather than sector-specific signals, since biotech fundamentals — open financing windows, active M&A, and positive clinical datasets — remain intact regardless of geopolitical or interest rate headwinds.
• •Q1 2026 M&A Pace: Nine public company biotech acquisitions closed in Q1 2026, the highest first-quarter count in over ten years of tracking, totaling approximately $32B in aggregate deal value. Investors and business development teams should note that deal premiums vary widely — Biogen paid a 140% premium for Apellis while Merck paid only 6% for its recent acquisition — signaling no uniform pricing standard.
• •Blood-Brain Barrier Shuttle Technology Validation: Roche's trontinumab delivers 10–20x more antibody exposure versus naked antibodies, achieving amyloid plaque clearance in roughly 75% of patients within six months with a fraction of the ARIA safety events seen with lecanemab or donanemab. Denali's FDA-approved Hunter disease enzyme therapy using the same transferrin receptor shuttle confirms the mechanism works across multiple modalities including antibodies, enzymes, and ASOs.
• •Oral GLP-1 Competitive Dynamics: Lilly's orforglipron (Foundeo) received FDA approval as a 17mg tablet via bioequivalence study — half the API of the 35mg capsule tested in trials — while Novo's oral semaglutide requires a 30-minute post-dose fasting window. Consensus 2026 U.S. sales estimates are $1.75B for Foundeo and $1.5B for Novo's pill, with Lilly narrowing the price gap to $50 above Novo's product.
• •Biogen/Apellis Strategic Logic: Biogen's $5.6B acquisition of Apellis addresses a projected $1.5B royalty revenue loss from Ocrevus losing exclusivity in 2029–2030. The deal is not pipeline-driven but rather a commercial and financial transaction, with Apellis's kidney drug empaveli providing a commercial platform to support Biogen's own phase 3 felzartamab renal program. Investors should monitor competitive data from Novartis and Regeneron in geographic atrophy later in 2026.
• •FDA Orphan Drug Environment Shift: Post-Vinay Prasad, FDA leadership is conducting one-on-one outreach meetings with companies that received complete response letters in orphan indications, signaling a more flexible posture. Scholar Rock's apitegromab BLA resubmission for spinal muscular atrophy — accepted despite neither fill-finish facility being fully remediated — and a pending Replimmune melanoma decision serve as near-term barometers for how far this flexibility extends.